(NASDAQ: TVRD) Tvardi Therapeutics's forecast annual revenue growth rate of 48.92% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 86.2%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.83%.
Tvardi Therapeutics's revenue in 2025 is $6,580,000.On average, 2 Wall Street analysts forecast TVRD's revenue for 2029 to be $153,461,691, with the lowest TVRD revenue forecast at $95,368,494, and the highest TVRD revenue forecast at $211,554,888. On average, 2 Wall Street analysts forecast TVRD's revenue for 2030 to be $411,434,873, with the lowest TVRD revenue forecast at $362,344,011, and the highest TVRD revenue forecast at $460,525,735.
In 2031, TVRD is forecast to generate $879,818,896 in revenue, with the lowest revenue forecast at $435,487,989 and the highest revenue forecast at $1,624,358,944.